CDH2 and breast carcinoma: In particular, heterotypic adherens junctions between breast cancer cell-derived CDH1 and CDH2 in an osteogenic niche can support bone colonization of circulating breast cancer cells and stimulate the mechanistic target of rapamycin (mTOR) pathway-driven micrometastasis formation [109].